- Home
- SWIM vs JANX Comparison
SWIM vs JANX Comparison
Compare SWIM & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWIM | JANX |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.9M | 790.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SWIM | JANX |
|---|---|---|
| Price | $5.99 | $14.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $6.75 | ★ $48.73 |
| AVG Volume (30 Days) | 469.2K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.00 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $545,912,000.00 | $10,000,000.00 |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | $66.89 | ★ N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $5.04 | $12.12 |
| 52 Week High | $8.97 | $35.34 |
Technical Indicators
Market Signals| Indicator | SWIM | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 53.98 |
| Support Level | $5.04 | $13.10 |
| Resistance Level | $6.93 | $15.49 |
| Average True Range (ATR) | 0.21 | 0.61 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 59.93 | 29.53 |
Price Performance
Historical ComparisonAbout SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. The company derives a majority of its revenue from the United States.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.